These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2566199)
1. Response to neuroleptic drugs as a device for classifying schizophrenia. Brown WA; Herz LR Schizophr Bull; 1989; 15(1):123-9. PubMed ID: 2566199 [TBL] [Abstract][Full Text] [Related]
3. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer HY; Rabinowitz J; Lee MA; Cola PA; Ranjan R; Findling RL; Thompson PA Am J Psychiatry; 1997 Apr; 154(4):475-82. PubMed ID: 9090333 [TBL] [Abstract][Full Text] [Related]
4. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
5. Problems in classification of schizophrenics as neuroleptic responders and nonresponders. Csernansky JG; Kaplan J; Hollister LE J Nerv Ment Dis; 1985 Jun; 173(6):325-31. PubMed ID: 2860202 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185 [TBL] [Abstract][Full Text] [Related]
7. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. Wiesel FA Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation trial on the efficacy of neuroleptics on the outcome of schizophrenia]. Dollfus S; Petit M Encephale; 1991; 17(4):247-53. PubMed ID: 1683625 [TBL] [Abstract][Full Text] [Related]
9. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Benatov R; Sirota P; Megged S Convuls Ther; 1996 Jun; 12(2):117-21. PubMed ID: 8744173 [TBL] [Abstract][Full Text] [Related]
10. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia. Jarema M; Kacperczyk J; Kruszynski S Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443 [TBL] [Abstract][Full Text] [Related]
11. Perspectives on a time-dependent model of neuroleptic action. Pickar D Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694 [TBL] [Abstract][Full Text] [Related]
13. Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics. Kane JM Psychopharmacol Bull; 1992; 28(3):227-9. PubMed ID: 1362275 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Glovinsky D; Kalogeras KT; Kirch DG; Suddath R; Wyatt RJ Schizophr Res; 1994 Feb; 11(3):273-6. PubMed ID: 7910756 [TBL] [Abstract][Full Text] [Related]
15. Cannabis and neuroleptic agents in schizophrenia. Knudsen P; Vilmar T Acta Psychiatr Scand; 1984 Feb; 69(2):162-74. PubMed ID: 6142585 [TBL] [Abstract][Full Text] [Related]
16. Drug strategies and treatment-resistant schizophrenia. Pantelis C; Barnes TR Aust N Z J Psychiatry; 1996 Feb; 30(1):20-37. PubMed ID: 8724325 [TBL] [Abstract][Full Text] [Related]
17. [The effect of neuroleptics in a attempt at understanding the vulnerability to schizophrenia]. Meurice E Acta Psychiatr Belg; 1992; 92(6):339-54. PubMed ID: 1364282 [TBL] [Abstract][Full Text] [Related]